SILO PHARMA INC (SILO)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$2.40-2.04%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · SILO
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 643.7% |
| Our one-year growth estimate | diamond | -0.1% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 643.8 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Elevated risk of a next-quarter earnings miss: this name is a smaller-cap name (higher miss base rate) and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 399 industry peers · Company calendar date is not available
SILO — capital allocation — Unregistered Sales of Equity Securities
Dated 2026-08-19
Unregistered Sales of Equity Securities. The information set forth under
Why it matters: The offering could provide Silo Pharma with up to $11.7 million for operations. This funding is crucial for their growth plans.
Supportive ifThe private placement is successful. Silo raised the full $11.7 million.
Worry ifThe offering fails to close or raises significantly less than $4 million upfront.
Why it matters: Updates on the buyback program may show that management believes in the stock's worth.
Supportive ifManagement says they have completed at least $500,000 in stock repurchases.
Worry ifNo updates on the repurchase program or a halt in the program.
Why it matters: Maintaining compliance with Nasdaq is vital for Silo's stock listing. Non-compliance could lead to delisting.
Worry ifNasdaq confirms that compliance is met after the next review.
Less concerning ifNasdaq says there are problems with meeting listing rules.
Why it matters: Finalizing this deal could help SILO grow and improve its market position.
Supportive ifThey announced the successful purchase of QwikAgents and its assets.
Worry ifThere is a delay or cancellation of the asset purchase agreement.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$239 on $10,000 · ±2.4% | How much price usually moves either way. |
| Bad day | $931 loss on $10,000 · 9.3% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $8,038 loss on $10,000 · 80.4% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: The offering could raise up to $11.7 million, which is crucial for funding operations.
Supportive ifThe private placement will close on or around July 10, 2026.
Worry ifThe offering fails to close or is delayed beyond the expected date.
Why it matters: If the warrants are used, it could bring in up to $7.7 million.
Supportive ifWarrants are used for cash. This leads to more money coming in.
Worry ifNo warrants are used in the expected time.
Why it matters: Starting the trial is a key milestone for Silo's lead drug targeting PTSD.
Supportive ifManagement starts the first human clinical trial for SPC-15.
Worry ifThe trial initiation is delayed or not announced as expected.
Why it matters: Staying compliant is important for Silo to stay listed on Nasdaq.
Watch forSilo meets Nasdaq's minimum bid price rules.
Also watch forSilo fails to meet Nasdaq compliance requirements again.